Regeneron Pharmaceuticals, Inc.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Regeneron's moat is anchored by Dupixent (partnered with Sanofi, with exclusivity extending through the early 2030s) and the Eylea HD next-generation franchise, supported by proprietary protein-engineering platforms (VelociSuite) and decades of clinical trial data. The original Eylea 2mg is facing imminent biosimilar entry — Samsung's biosimilar is precluded from US launch until January 2027 — but Eylea HD is converting patients ahead of biosimilar competition.
Regeneron's competitive position rests on regulatory exclusivity (Dupixent + Eylea HD), proprietary discovery platforms (VelociSuite, VelocImmune), and immuno-oncology pipeline depth — partially offset by Eylea 2mg biosimilar exposure:
- Dupixent: The Atopic-Disease Powerhouse: Dupixent (partnered 50/50 with Sanofi for global commercialization) treats atopic dermatitis, asthma, eosinophilic esophagitis, prurigo nodularis, and (most recently) COPD. Global Dupixent sales are running at ~$15B+ annually with 20%+ growth, and patent exclusivity extends into the early 2030s in major markets. Regeneron books its share through the Sanofi collaboration revenue line. New indications (chronic spontaneous urticaria, bullous pemphigoid) extend the franchise runway.
- Eylea HD: Out-Running the Biosimilar: Regeneron is aggressively converting Eylea 2mg patients to Eylea HD (8mg, longer dosing interval), which has independent patent protection extending into the late 2030s. Eylea HD US revenue jumped 52% to $468M in Q1 2026; the just-resolved Samsung biosimilar litigation precludes Samsung's US launch until January 2027, giving Regeneron extra time to convert the franchise. Combined US Eylea + Eylea HD net sales fell 10% to $941M in Q1 — the conversion math is the central thesis.
- VelociSuite: A Reproducible Discovery Engine: VelocImmune (humanized mice for fully human antibody discovery) and VelociMab/Mouse have produced a high-yield pipeline including Dupixent, Praluent, Libtayo, Linvoseltamab, and the linvoseltamab BCMA bispecific. Newer bispecifics targeting CD3 + tumor-associated antigens give Regeneron a credible immuno-oncology franchise alongside its mature inflammation/ophthalmology businesses.
- Capital Allocation Discipline: Regeneron repurchased $803M of stock in Q1 2026 and authorized an additional $3B buyback in April 2026. Founder-led management (Schleifer/Yancopoulos) has a 30+ year track record of disciplined R&D allocation and conservative capital structure. The dividend was initiated in 2024 — modest but a signal of capital-return maturity.
Moat Verdict
Regeneron's moat structure is led by regulatoryLockIn (Dupixent + Eylea HD), proprietaryData (Regeneron Genetics Center exome dataset), businessLogic (VelocImmune platform), and talentScarcity (Yancopoulos-led discovery team). These moats are highly AI-resilient — AI does not disrupt patent-protected biologics; it actually accelerates Regeneron's pipeline targeting through computational protein engineering and patient stratification on the Genetics Center dataset. The structural risks are pipeline-execution risk (itepekimab, bispecifics) and the Eylea 2mg biosimilar transition, neither of which is AI-driven.
81.8 resilient · 65.0 vulnerable · 80/20 = 78.4 · = 78
Open a moat to read its note.
physicians prescribe based on clinical evidence and outcomes, not interface familiarity; learned-interface moats do not apply to biologics.
Regeneron's VelocImmune humanized-mouse platform, VelociMab antibody discovery technology, and bispecific antibody engineering know-how represent decades of proprietary technical capability that competitors cannot reverse-engineer from the resulting drug labels.
Regeneron's moat does not rely on controlling access to a public data source; not relevant to the biologics business model.
Antibody engineering, bispecific design and immunology and oncology trial leadership take scarce expertise, and Yancopoulos's scientific leadership has long drawn top-tier talent. Every large biopharma hires from the same pool, and no figure shows the bench blocks entry, so it rates intact.
biologics are sold as individual prescription products, not in bundles; per-drug FDA approvals are the unit of competition.
Regeneron Genetics Center has sequenced and analyzed exomes from 2.5M+ consented individuals (the largest such dataset outside the UK Biobank), powering target discovery and patient stratification. Decades of Dupixent and Eylea clinical and real-world data inform label expansions and pipeline targeting.
Dupixent (multiple FDA-approved indications, patent into early 2030s), Eylea HD (FDA approval, patent into late 2030s), Libtayo, Linvoseltamab, and Odronextamab each carry independent FDA approvals and global regulatory clearances. Eylea 2mg patent erosion is the only meaningful regulatory weakening — Eylea HD is replacing it ahead of biosimilar competition.
Retina specialist and dermatologist network effects: as more physicians gain experience with Eylea HD and Dupixent, peer recommendations and KOL endorsements compound prescribing behavior. Bispecific antibody trial-site networks build similar effects in oncology.
Eylea HD and Dupixent are embedded in retinal-specialist and atopic-disease standard of care, payer formularies, and Medicare Part B reimbursement schedules. Removing them faces enormous patient, physician, and political resistance.
Regeneron is a drug manufacturer, not a system-of-record platform; this moat type does not apply to biologics.
Drug franchise economics come from patents and approvals (regulatoryLockIn), not a unit-cost lead from manufacturing scale.
Prescribing follows efficacy, label and formulary position, not the manufacturer's name; no brand premium independent of the approvals.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Regeneron's moat is anchored by Dupixent (partnered with Sanofi, with exclusivity extending through the early 2030s) and the Eylea HD next-generation franchise, supported by proprietary protein-engineering platforms (VelociSuite) and decades of clinical trial data. The original Eylea 2mg is facing imminent biosimilar entry — Samsung's biosimilar is precluded from US launch until January 2027 — but Eylea HD is converting patients ahead of biosimilar competition.
Growth Score
Q2 2026 (Jul 30): revenue rose 17% YoY to $4.3B and non-GAAP EPS was $14.29 (GAAP $12.23), both well ahead of consensus. Dupixent global sales (recorded by Sanofi) rose 38% to a record $6.0B, lifting Regeneron's share of collaboration profits to $2.03B from $1.28B. EYLEA HD US sales rose 52% to a record $596M while legacy EYLEA 2mg fell 45% to $412M, so the combined US EYLEA franchise still declined. Libtayo grew 30% to $489M. Management expects multiple aflibercept 2mg biosimilar launches in H2 2026 (Samsung is held to January 2027 by settlement), guiding legacy EYLEA to low-to-mid-teens sequential declines in Q3 and Q4 against low-to-mid-teens sequential growth for EYLEA HD. FY2026 non-GAAP gross margin guidance was raised to 84-85% from 83-84%.
Valuation Score
At ~$796 (September 24, 2026), Regeneron trades at ~15.3× FY2026 consensus adj. EPS (~$52, raised ~16% in the month after a Q2 beat of $14.29 vs ~$10 expected) — still a discount to its ~22× five-year average, reflecting the Eylea 2mg biosimilar overhang into 2027. The price sits ~10% below the base target ($880), ~53% above the bear ($520) and ~31% below the bull ($1,150). Q2 revenue grew 17% to $4.29B on Eylea HD (US $596M, +52%) and Dupixent (global sales $6.0B, +38%), so the earnings base the market is discounting has moved up sharply since May; the open question is how much of FY2026 EPS survives biosimilar entry in 2027.
The Dupixent + Eylea HD Conversion Story
Regeneron's competitive position rests on regulatory exclusivity (Dupixent + Eylea HD), proprietary discovery platforms (VelociSuite, VelocImmune), and immuno-oncology pipeline depth — partially offset by Eylea 2mg biosimilar exposure:
- Dupixent: The Atopic-Disease Powerhouse: Dupixent (partnered 50/50 with Sanofi for global commercialization) treats atopic dermatitis, asthma, eosinophilic esophagitis, prurigo nodularis, and (most recently) COPD. Global Dupixent sales are running at ~$15B+ annually with 20%+ growth, and patent exclusivity extends into the early 2030s in major markets. Regeneron books its share through the Sanofi collaboration revenue line. New indications (chronic spontaneous urticaria, bullous pemphigoid) extend the franchise runway.
- Eylea HD: Out-Running the Biosimilar: Regeneron is aggressively converting Eylea 2mg patients to Eylea HD (8mg, longer dosing interval), which has independent patent protection extending into the late 2030s. Eylea HD US revenue jumped 52% to $468M in Q1 2026; the just-resolved Samsung biosimilar litigation precludes Samsung's US launch until January 2027, giving Regeneron extra time to convert the franchise. Combined US Eylea + Eylea HD net sales fell 10% to $941M in Q1 — the conversion math is the central thesis.
- VelociSuite: A Reproducible Discovery Engine: VelocImmune (humanized mice for fully human antibody discovery) and VelociMab/Mouse have produced a high-yield pipeline including Dupixent, Praluent, Libtayo, Linvoseltamab, and the linvoseltamab BCMA bispecific. Newer bispecifics targeting CD3 + tumor-associated antigens give Regeneron a credible immuno-oncology franchise alongside its mature inflammation/ophthalmology businesses.
- Capital Allocation Discipline: Regeneron repurchased $803M of stock in Q1 2026 and authorized an additional $3B buyback in April 2026. Founder-led management (Schleifer/Yancopoulos) has a 30+ year track record of disciplined R&D allocation and conservative capital structure. The dividend was initiated in 2024 — modest but a signal of capital-return maturity.
Moat Verdict
Regeneron's moat structure is led by regulatoryLockIn (Dupixent + Eylea HD), proprietaryData (Regeneron Genetics Center exome dataset), businessLogic (VelocImmune platform), and talentScarcity (Yancopoulos-led discovery team). These moats are highly AI-resilient — AI does not disrupt patent-protected biologics; it actually accelerates Regeneron's pipeline targeting through computational protein engineering and patient stratification on the Genetics Center dataset. The structural risks are pipeline-execution risk (itepekimab, bispecifics) and the Eylea 2mg biosimilar transition, neither of which is AI-driven.
81.8 resilient · 65.0 vulnerable · 80/20 = 78.4 · = 78
Open a moat to read its note.
physicians prescribe based on clinical evidence and outcomes, not interface familiarity; learned-interface moats do not apply to biologics.
Regeneron's VelocImmune humanized-mouse platform, VelociMab antibody discovery technology, and bispecific antibody engineering know-how represent decades of proprietary technical capability that competitors cannot reverse-engineer from the resulting drug labels.
Regeneron's moat does not rely on controlling access to a public data source; not relevant to the biologics business model.
Antibody engineering, bispecific design and immunology and oncology trial leadership take scarce expertise, and Yancopoulos's scientific leadership has long drawn top-tier talent. Every large biopharma hires from the same pool, and no figure shows the bench blocks entry, so it rates intact.
biologics are sold as individual prescription products, not in bundles; per-drug FDA approvals are the unit of competition.
Regeneron Genetics Center has sequenced and analyzed exomes from 2.5M+ consented individuals (the largest such dataset outside the UK Biobank), powering target discovery and patient stratification. Decades of Dupixent and Eylea clinical and real-world data inform label expansions and pipeline targeting.
Dupixent (multiple FDA-approved indications, patent into early 2030s), Eylea HD (FDA approval, patent into late 2030s), Libtayo, Linvoseltamab, and Odronextamab each carry independent FDA approvals and global regulatory clearances. Eylea 2mg patent erosion is the only meaningful regulatory weakening — Eylea HD is replacing it ahead of biosimilar competition.
Retina specialist and dermatologist network effects: as more physicians gain experience with Eylea HD and Dupixent, peer recommendations and KOL endorsements compound prescribing behavior. Bispecific antibody trial-site networks build similar effects in oncology.
Eylea HD and Dupixent are embedded in retinal-specialist and atopic-disease standard of care, payer formularies, and Medicare Part B reimbursement schedules. Removing them faces enormous patient, physician, and political resistance.
Regeneron is a drug manufacturer, not a system-of-record platform; this moat type does not apply to biologics.
Drug franchise economics come from patents and approvals (regulatoryLockIn), not a unit-cost lead from manufacturing scale.
Prescribing follows efficacy, label and formulary position, not the manufacturer's name; no brand premium independent of the approvals.
Growth Analysis
Growth Drivers
Key Risk
If the H2 2026 aflibercept 2mg biosimilar launches (plus Samsung from January 2027) price aggressively enough to pull EYLEA HD's net price and conversion pace down with them, and Dupixent's growth slows sharply as the COPD launch laps and new IL-13/OX40 competitors arrive, the combined US EYLEA franchise could fall 25%+ in 2027 while the collaboration profit engine decelerates, leaving total revenue growth in low single digits.
Score Derivation
72.9 base − 5 risk = 68
Base 72.9 (8-12% CAGR, midpoint 10%, decayed from Q2's +17% YoY for legacy EYLEA run-off and Dupixent lapping; up from 5-10% as Dupixent's acceleration outruns the EYLEA 2mg decline) + 0 trajectory (Dupixent accelerating, EYLEA HD and Libtayo stable, EYLEA 2mg decelerating) + 0 stable margins - 5 moderate risk (moved from high: the EYLEA 2mg biosimilar wave is now scheduled and guided, so it is charged in the CAGR and the EYLEA 2mg driver rather than the risk term; what remains unmaterialised is biosimilar price pressure spilling onto EYLEA HD and Dupixent slowing faster than expected, graded moderate like LLY's and NVO's franchise risks) = 68
Price Scenarios (12–24 Months)
Valuation Multiples
| Forward P/E (FY2026) | ~15.3× |
| Q2 2026 Adj. EPS | $14.29 |
| Q2 2026 Revenue | $4.29B |
| Market Cap | ~$81B |
| Consensus Price Target | ~$802–833 |
REGN still screens inexpensive (~15× FY2026 consensus EPS) for a high-margin biologics company whose two main engines — Dupixent and Eylea HD — both accelerated in Q2. The discount is the 2027 Eylea 2mg biosimilar transition: no reliable FY2027 consensus was available at this review, and the base case assumes EPS roughly flat into 2027 as Dupixent growth offsets legacy Eylea erosion. A re-rating toward ~17× is plausible once that transition proves manageable.
Approximate figures as of September 2026.
Where We Are vs Targets
Loading live price…
Eylea HD conversion stalls, multiple biosimilars launch aggressively after January 2027, and a key pipeline asset (e.g., itepekimab in COPD) disappoints in Phase 3.
- Eylea HD captures less than 50% of US Eylea franchise revenue by end of 2026; combined US Eylea franchise declines 25%+ in 2027 as Samsung, Mylan, and Amgen biosimilars launch in parallel
- Itepekimab Phase 3 in COPD fails to demonstrate meaningful exacerbation reduction vs. Dupixent, eliminating a billion-dollar incremental opportunity in the inflammation franchise
- Dupixent growth decelerates sharply from Q2 2026's +38% toward ~10% as competition (e.g., Eli Lilly's lebrikizumab, novel JAK inhibitors) takes share in atopic dermatitis
- FY2027 EPS falls ~10% from the ~$52 FY2026 consensus to ~$47 and the multiple compresses to ~11× as the market re-rates Regeneron as a biosimilar-exposed mature biotech — implying ~$520
Eylea HD keeps absorbing the US franchise ahead of biosimilar entry, Dupixent sustains strong growth into 2027, bispecifics ramp, and EPS holds near the ~$52 FY2026 consensus through the biosimilar transition while Regeneron re-rates modestly.
- Eylea HD keeps growing off a Q2 2026 US run-rate of $596M/quarter (+52% YoY), limiting biosimilar damage to the legacy 2mg portion
- Dupixent (global sales $6.0B in Q2 2026, +38% YoY) keeps compounding as COPD ramps, lifting Regeneron's collaboration revenue
- Linvoseltamab and odronextamab combined reach $700M+ FY2026 revenue as bispecific antibodies expand in lymphoma and multiple myeloma
- ~17× on EPS held near the ~$52 FY2026 consensus into 2027 (≈$884), supported by the $3B buyback authorization — fair value ~$880
Eylea HD essentially preserves the franchise through 2027, itepekimab succeeds in COPD, and immuno-oncology bispecifics emerge as a meaningful third growth engine.
- Eylea HD captures 80%+ of US Eylea franchise by end of 2026, holding combined US Eylea revenue flat through 2027 despite biosimilar entry
- Itepekimab Phase 3 succeeds in COPD with differentiated mechanism vs. Dupixent, expanding the inflammation franchise toward a $25B+ combined run-rate
- Linvoseltamab + odronextamab + new bispecifics reach $2B+ run-rate by 2028, establishing Regeneron as a top-3 bispecific antibody franchise
- Multiple expands to ~21× on FY2027 EPS of ~$55 (≈6% above the FY2026 consensus as Eylea HD holds the franchise) — implying ~$1,150